TY - JOUR
T1 - Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
AU - Sher, Taimur
AU - Miller, Kena C.
AU - Lawrence, David
AU - Whitworth, Amy
AU - Hernandez-Ilizaliturri, Francisco
AU - Czuczman, Myron S.
AU - Miller, Austin
AU - Lawrence, William
AU - Bilgrami, Syed Ali
AU - Sood, Raman
AU - Wood, Margaret T.
AU - Block, Annemarie W.
AU - Lee, Kelvin
AU - Chanan-Khan, Asher Alban
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.
AB - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.
KW - Chronic lymphocytic leukemia
KW - Fludarabine-refractory
KW - High-risk cytogenetics
KW - Lenalidomide
UR - http://www.scopus.com/inward/record.url?scp=74949083498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74949083498&partnerID=8YFLogxK
U2 - 10.3109/10428190903406806
DO - 10.3109/10428190903406806
M3 - Article
C2 - 20055660
AN - SCOPUS:74949083498
VL - 51
SP - 85
EP - 88
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 1
ER -